Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Orion Oyj, Q1'24

By Inderes4/25/2024, 10:30 AM
Orion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:00 - 03:02

Ok. Via email only, system online. Boston or Southeast headquarters. Please provide the source's current location. Either in Tallahassee or on a teleconference line. You can view the webcast in the chat. Lisa Zimmerman, Damon Hill in Charlottesville. And now Hoyt. Good afternoon, ladies and gentlemen, and welcome to Orion Corporation's earnings conference call and webcast for the financial period of January to March 2024. First, I would like to apologize. The slight delay. We were facing some minor technical issues, which have now been resolved, and we're ready to proceed. Uh, my name is Tucker, and I'm the head of investor relations here at Orion Corporation. In a few moments, our CEO, Lisa May, will present the results of the review period; afterward, you will have the opportunity to ask questions from her and our CFO, Larry Carlson. We will first take questions from the conference call lines. And then, after that, we will accept questions typed through the webcast's chat function. For those presenting questions via the conference call lines, please state your name and the organization you represent before asking your question. And just before I let Lisa step in. Uh, today is quite a special day, because this interim report is the last one that Mr. Carlson will deliver to you as the CFO of Orion Corporation. He has been the CFO of Orion Corporation since September 1, 2002. So, more than 20 years. And today, he is presenting his 87th interim report or financial report. So while I let that sink in for you guys, I'll draw your attention also to the traditional disclaimer about forward-looking statements. And then hand over to Lisa. Lisa, please, your turn.

Lisa
03:02 - 21:02

Thank you, and good afternoon on my behalf as well. Welcome to the Orion Q1 Results Webcast. Q1 of this year started very well with strong top-line growth of 11%. We generated €308.5 million in sales during the first quarter and €56 million in operating profit, with growth of 1%, resulting in an 18.2% profit margin. Cash flow was significantly better than in Q1 of 2023, where the transfer of pension funds was one contributor. And then a €30 million milestone payment we received from Bayer was made in the first quarter of 2023. And of course, good sales of Nubeqa® can also be seen here with royalties and product sales. And, regarding the operating profit, growth of 1% or even being flat compared to the revenues we have as planned and as communicated, invested more in R&D as well as our sales and marketing, and the results of that can, of course, be seen in the top-line growth. And here we take a closer look. Very good news regarding an almost $1 million growth. Also Easyhaler®, if you look here, the column shows almost as high growth, both in percentage and in absolute value with the Easyhaler® product portfolio. Also, the whole other portfolio. Excluding Animal Health, Fermion grew by 7.3%, and Animal Health also showed nice growth. We see a slight decline within the product portfolio, but clearly the decline is slowing down compared to the previous year. And hopefully, we'll clear these issues as we go along this year. The usual suspects are on the column. Some same drugs and dexmedetomidine managed to maintain continued, uh, generic competition. Uh, taking sales down here. On the operating profit. Volumes are clearly growing, but margins are declining due to the factors mentioned in previous slides. Explanations on Dex and Dexter's decline, very profitable products. And the new ones, replacing those, are not exactly as profitable. Royalties are evident; you can see the effect on the operating profit. And then fixed costs have grown by 12.3%. And that's in line with our previous estimate for the R&D costs, sales, and marketing costs. Here we can also say that some of our IAM costs have increased somewhat. We have a major program ongoing with the CIP renewal, and some of our programs and data need to be run on parallel systems during that. Now, our innovative medicines posted a 37.4% growth, a wonderful number. Let's remember that we start every year beginning with the royalty rate. So it's really a cumulative royalty rate from the beginning of every year. So, both the royalty rate and the sales will grow as the year proceeds. We've seen all-time high product deliveries to Bayer during the last quarter of last year, and actually the second highest ever during this first quarter. So the prognosis from that aspect is very good. And of course, as I said, other income is primarily from research purposes and we are significantly increasing our investments. And I will talk more about that when I get to the R&D pipeline. And we are continuing with Ztalmy® to, um. Uh, get the pricing and reimbursement in place in Europe. Another business area is in very good shape, even though there was a slight decline of 2.2%. If we deduct the impact of Dexdomitor® and Simdax® as well as Russia, from the previous year, we still had some sales in Russia in 2023, especially in the beginning of 2023. The generics portfolio grew by 5%. That's very healthy growth. It's currently assumed that generic sales in Europe will grow between 4 to 6%. So we are exactly in that space with our generics business. In Finland, which is the largest market for our generics, we were able to outperform the competitors, especially in the reference price market. We're also performing well in the OTC healthcare and consumer health markets. I think that I probably, unfortunately, skipped one slide here about branded products. Another division growing with double-digit numbers, showing almost 18% growth compared to Q1 2023, has clearly been a lead indicator. And the growth of this product, with more than 30% growth, is driven by the green wave in Europe, especially in the UK. But currently, we are also seeing the same kind of demand in Germany. And with Easyhaler® as our halo product, we can respond to this demand as the market entry coupon. I already discussed that it is almost at par with the previous year. And the Divina® series, which for us is mainly a hormonal gel with estradiol, is also growing compared to the previous year. All in all, a very good start for branded products as well as for the innovative and generics divisions, which shows that all of our businesses are contributing to the growth of the group or Orion group. And then the smaller businesses. Animal health is not being shy at all compared to the other divisions. There's healthy growth there as well, and Fermion keeps up with the external sales to other pharma companies and animal health sales grew also on the companion animals side with sedatives. We also launched Bonqat® in Europe and then also in the livestock business. Now, clinical pipeline. The change here from the previous one is that we have now completed ODM-111 phase one successfully, and we are expecting and preparing to report the results at some point next year at suitable scientific congresses. Otherwise, the portfolio remains as it has been so far. Sustainability continues to be a very strong item for Orion. Of course, we are preparing, as any other company, for the CSD reporting. And here you can see some of the major themes that are important for us. It's based on patient safety. We look at it from the supply perspective, of course, from the wider scope of pharmacovigilance and product quality as well. But in these days, it's not self-evident that the pharmaceuticals and medicines are available in pharmacies when you need them. And our service level is at an exceptional environmental level. We continue to work on that front. We are already ahead of our 2030 carbon neutral target for Scope 1 and 2 at Orion and are now expanding to Scope 3. We've also put a lot of emphasis on social responsibility, building a roadmap in the company, including our stakeholders and groups that we work with, and also, of course, the safety, putting focus on the safety of our employees. Now that you've seen the quarter one result, which we are very proud of, our quarter one was better than we had planned. And based on that, we are specifying our outlook for 2024 and specifying so that we raised the lower limit from 270 million to 280 million. So we have a more specified narrow scope for this year, from 280 million to €310 million of operating profit. The outlook for net sales remains the same as it was at the beginning of this year. And to this outlook and our understanding of how the year has started. It's important to understand that really, all our businesses know that Nubeqa is a wonderful growth driver, but as you saw, Easyhaler is as important with its fast growth and all our divisions are growing in a healthy way. If we deduct the effect of Simdax and Dexmedetomidine. Or decline the effects of Simdax and Dexmedetomidine. So all businesses are contributing to the growth of our net profit. Here, you can see on the slide the basis for the outlook, which I already discussed. So it's a new growth, and the cap on the product family is more as a flattish Easyhaler. Or animal health. Definitely growing. And the generics-based portfolio as well. Growing, which is a bit challenging. What is challenging is really to predict the timing of Nobel royalties, product sales, and some of the milestones. This year it's the €70 million sales milestone. So that's, we have a certain, how would I say, room for our outlook? Given these facts and R&D expenses are anticipated to increase significantly, and significantly means that it's on a different level than we are used to. It is understandable, as we are going to start a phase two program for our pain molecule with several phase two studies. And we still have several phase three trials ongoing with our partners. And also, we have molecules in our research pipeline which actually require much more of our budget since those are biologics. And then we need to do the CMC work, labor-intensive work, from an end date. So clearly more emphasis on R&D and also on sales and marketing, which has resulted in growth in all divisions. And this kind of puts together what I already said, that this makes it concrete and provides a framework for our strategy. We clearly have growing revenues. And all divisions play an important role there. And that allows us and enables us to spend more on R&D. We want to build the company's future beyond the 2030s and also invest in other areas like sales and marketing. Ensure that we have enough production capacity. And we have enough production capacity. Capacity? I'm sorry. We still have a bit of a technical challenge here. I was actually on this slide, thanks to... So, also, we want to invest in the production capacity as we are currently increasing capacity, increasing our digital capacity, and also our new backup capacity at Fermion. So all this growing revenue enables increasing the investments, growing EBIT and also growing our dividend. A clear package. And we really work within this framework. And now I'm going to jump one slide over to remind you of our financial objectives, which relate to the previous slide of our strategy. Now they move totally independently. Anyway, when I say that the revenues will grow, it's growth beyond 8%; no cover. Also, that we are able to grow faster with our operating profit, keeping the equity ratio at least at 50% and return of equity at least at 25%. So this gives a very strict, nice framework for all our investments and growth initiatives. And then the dividend payout of between 50 and 100%. Now I go back. Let's see how this works. It works well and we come to the capital allocation focus telling the same story. A very, very good story here. Internal pipeline as a first priority. Dividends: Maintaining, maintaining, and increasing the capacity where it's needed. Then in licensing or acquiring commercial or R&D assets, whatever is then suitable at which time and then acquisitions, if they really fulfill a criteria to produce growth in a way we want, for example, in such geographies where we are not yet operating, or if they provide some kind of a competence or capabilities that we need to fulfill our strategic targets. Now. All right. I think it's time to close on my behalf and invite Harry Carson here with me to answer your questions before we close the session. Please feel free to ask any questions.

Unknown 1
21:04 - 21:10

To the operator. So, operator, please, it's time for the questions from the teleconference lines.

Operator
21:10 - 21:33

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Anthony Rousey from CB. Please go ahead.

Unknown 2
21:36 - 22:03

Thankell you. And, uh. Hi, all. A few questions from me, and the first one is about your minor updating guidance. Like, of course, you mentioned that the year has started slightly better than you had expected, but is there something which is trending more positively than you had expected, or was it something? Uh. Q1 specific event, like just trying to figure out how the assumptions behind the guidance are developing.

Lisa
22:05 - 22:40

Thank you. Very good question indeed. I said that the Q1 was better than we planned, and it comes from many sources. Uh, so I'm not going to go and separate things here. It was a bit better, uh, gross margin or gross profit, you know, on our sales, it's, uh, slightly better, no better royalties, and excellent and slightly better sales from each year. So you could call those trends as well, or those are trending. So it gave us the opportunity to be a bit more accurate on our outlook.

Unknown 2
22:43 - 22:52

Okay. And now, as you mentioned, this is about Nubeqa®. Like what was behind the strong growth in Nubeqa®. Like extraordinarily strong.

Lisa
22:54 - 24:09

Well, first of all, Easyhaler® has enjoyed strong growth since, uh, the latter part of last year. And there are several reasons. The most important being really this, uh, green, uh, agenda of health authorities in the UK and uh, the same agenda seems to be forming in Germany. So these countries and the authorities have set a very high and demanding target for reducing their carbon, uh, emissions. And they have actually calculated that inhalers are the worst ones to produce carbon in their portfolios. So being able to provide a dry powder inhalation with a very, very small carbon footprint, or none at all, actually, has provided us an opportunity to accelerate our sales. Of course, we need to remember that last year, the first quarter wasn't that good for Easyhaler®. So the comparison, uh, comparable period wasn't that strong. That, of course, uh, kind of intensifies this growth percentage for this quarter.

Unknown 2
24:12 - 24:25

Okay. That's clear. And then about ganaxolone. So can you give us any timetable for ganaxolone? And have you included any expectations regarding this product in your guidance for this year?

Lisa
24:28 - 24:52

It would be great to give a timeline. It's not up to us. It's really up to the reimbursement and pricing authority. So, uh, these processes take a long time in Europe, and you need to go country by country. So we are in the process. "I can't give you an exact timeline currently." And thus it's difficult to give an estimate for a product either.

Jerry
24:53 - 25:10

But like we have said many times before, this first indication for ganaxolone is expected to be anyway a very small one. So even if the launch had gone as planned, it still would have had only a very minor impact on our overall numbers.

Unknown 2
25:12 - 25:21

Okay, I understand. Hey, finally. Thank you. It's been a pleasure to work with you during these recent years, so thank you. That's all for me.

Operator
25:30 - 25:36

The next question comes from Sami Sakamoto from Danske Bank. Please go ahead.

Unknown 2
25:38 - 26:17

Okay. I just wanted to start with, uh, thanking you for good cooperation over the years. Um, I have five questions. We'll take these one by one. Uh, I still want to go back to the guidance that was, uh, touched on in the previous question. Uh, have you assumed any more positive development during the rest of the year, or is this guidance revision sort of backward looking in that you have just sort of updated, uh, your assumptions relative to Q1? That went a bit better than expected?

Jerry
26:19 - 27:07

Well, I guess I mean, that part was already discussed. But I think one thing is that we started from, uh, maybe a relatively wide range. And now when one quarter of the year is gone. So, we gradually have a more accurate view of how the year will look like. And that's also behind it. So nothing really has changed in the overall big picture. But our overall view of how the year will be going, is hopefully now a little bit more accurate than at the beginning of the year. And that's also behind the specification. So, we thought we were confident enough that we could narrow the guidance a little bit. And especially taking it upward from the lower end.

Unknown 2
27:10 - 27:31

Okay, uh, moving on to other products. Uh, if we think about the Easyhaler, and animal health, are you expecting, uh, to see growth rates like in the full year or are there other things that we should take into consideration when you think about the rest of the year?

Lisa
27:32 - 28:16

Well, generally, as I stated already in the outlook, we are expecting a stable and intact product family to be quite flattish. Uh, the decline has already stopped to some extent. You know, the decline that we saw last year in animal health should continue on the same trajectory that it has been on to date this year, and with Easyhaler, of course, this first quarter percentage might be a bit more than we will see, because the first quarter of 23 was not good. Uh, it was not at the same level as the rest of the year of 23.

Jerry
28:17 - 28:43

So we really saw during last year already a nice growth that when we started last year, we were actually a little bit behind the year before, and then ended up achieving relatively nice growth for the full year. So we really saw a very good second half of the year last year. And that's why the percentages definitely will not be as strong as during the first quarter. But nice growth anyway, effective for the full year as well.

Unknown 2
28:45 - 29:10

Okay, thanks. Then moving on to the pipeline. Regarding ODM-208, you're planning to initiate a new Phase 1 or 2 study with Merck. This will be in combination with other drugs for prostate cancer. Uh, can you comment on which drugs we're talking about and whether this could broaden the market potential for ODM-105 significantly?

Lisa
29:11 - 29:24

Well, indeed, yes, such a study is going to be started. Unfortunately, I'm not in a position to comment on MSD's involvement in that program.

Unknown 2
29:27 - 29:37

Okay, and then I just wanted to verify. Are you still on track to initiate the phase two for ODM-105? During the second quarter?

Lisa
29:39 - 29:51

We have stated that we will start the phase two program for ODM-111 during this year. So we are still on track with that.

Unknown 2
29:53 - 30:05

Okay. And then, uh, finally, um, do you have any comments regarding, uh, the situation at, uh, marinas? I'm thinking about their recent setback with.

Lisa
30:07 - 30:19

Well, again, I think this is something that Marina's is the right party to comment on. So I wouldn't like to dwell on other companies' matters.

Unknown 2
30:22 - 30:24

Okay.

Operator
30:29 - 30:32

The next question comes from Brian from Jefferies.

Unknown 3
30:37 - 31:16

Hi. It's Barnum Jeffries. Um, I thought I'd just ask a bit more on the pipeline. So just on that ADC partnership for up to three ADCs. Um, have you started R&D for those programs? Just trying to get a sense of the timing for additional R&D and when we should expect to see something in the clinic. And then, just on those three issues, would one of those relate to 'glycolysis GLK' and discovery targeting too, or are we talking about new targets here? Leveraging the DMA use cytotoxic payload, which I think is an improvement on my use by parts and quality.

Lisa
31:18 - 32:20

Thank you. Of course, we are hoping to bring new molecules to our pipeline within the next few years. We have the biologics in the research and pre-candidate stage. I think you were referring to those when you were asking probably about the mechanism of those. But I would probably need to ask you to repeat the question or even write it down.

Unknown 3
32:22 - 32:26

Okay. Just to check. You heard it was with regards to the collaborations.

Lisa
32:27 - 32:31

So we have a collaboration. Yes. Okay. Yes.

Unknown 3
32:33 - 32:36

Okay. Yeah. That's it then. I think you've answered it then.

Operator
32:45 - 32:50

The next question comes from Graham Parry from Bayer. Please go ahead.

Graham Parry
32:53 - 33:11

Hi. Thanks for taking my questions. It's Graham Parry from Bank of America. Just the first one is to kick off on Easyhaler®. Hello? Just. Was there any inventory building there? I know you talked about the sort of Easyhaler® base and then the green agenda in the UK and Germany, but any inventory movement or any inventory build that was driving the sales on that line.

Lisa
33:12 - 33:14

Any inventory build.

Jerry
33:15 - 33:26

Yeah, I guess we at least are not aware that our customers would have been building their inventory. So as far as we know, it really is coming from the actual increase.

Lisa
33:26 - 33:27

The market.

Jerry
33:27 - 33:29

In the demand for the products.

Lisa
33:30 - 33:31

Yes. Great.

Unknown 3
33:31 - 33:31

Okay.

Graham Parry
33:32 - 33:58

Then, on DME zero eight, I know you've reserved this sort of 60 million cost. But as you start a phase three there. Just at which point do you think that would be exhausted? And you'd actually have to start booking R&D costs to the P&L. And would that be in 2024? Is that something you wouldn't anticipate having to actually book P&L costs until 2025-2026? Assuming, of course, this isn't converted to a royalty deal.

Lisa
33:59 - 34:54

Well, I can start and then you can continue. Just to remind you that the deal with MSD is now a collaboration and co-development deal, and we are really developing together. However, we are not accruing costs on that development currently. MSD is paying for that. And yes, we have accrued 60 million to cover those in case needed. There is an option in the agreement that either side can turn the agreement from co-development to a traditional licensing agreement. And of course, if such an option would be exercised. Then we could release that 60 million from the balance sheet.

Jerry
34:56 - 35:42

So, but yeah, it really is dependent very much on whether the option will be used or not. And so far the arrangement is such that, until that decision is made, we will not incur costs. Or of course, if we would calculate that the cost in that case would, our share would clearly exceed 60 million. Then of course it might be a different thing, but at least not for the time being. We are not in that duration. So the decision will be made once we know whether the option will be used or not. And maybe to remind that the option is something that either party can use. So even if Orion decides not to use the option, MSD still can do it and vice versa.

Graham Parry
35:44 - 35:59

So it's the timing and the decision tree on the option at this point. At which point, I guess, do you know whether you're going to need to start booking P&L costs for DMT08 in excess of the 60 million?

Lisa
36:00 - 36:10

Well, if either party exercises the option, I'm sure both parties will let the market know that. But at this stage we can't comment on that one.

Jerry
36:10 - 36:29

And I guess the only thing we can say is that we have earlier told that in this year's guidance, we have not included any of these ODM-208 costs as part of our R&D. So that gives a little bit of picture of the timeframe. But what happens then, beyond this year, then that needs to be communicated later.

Graham Parry
36:31 - 36:38

I've got it. Okay. Um, and, uh, sorry if I missed a bit. Could you quantify the pension release benefit to cash flow?

Jerry
36:39 - 37:10

If the, like. Like you mentioned at the on the last day of last year, the pension liabilities were transferred and we gained the approval from the Finnish. Financial Supervisory Authority to transfer the cash during Q1, and about 41 million euros worth of cash was transferred from the pension fund to Orion during that quarter. So that is included now in the positive and good cash flow for the first quarter of this year.

Graham Parry
37:12 - 37:13

But okay then, keep.

Lisa
37:15 - 37:15

Okay.

Operator
37:19 - 37:24

There are no more questions at this time, so I hand the conference back to the speakers.

Unknown 1
37:27 - 37:58

Right. Thank you. It seems that currently we don't have any more questions online. And I guess that there won't be any follow-ups on the conference call lines either so quickly. So I guess it's time to say that every good story must come to an end. And unfortunately, or fortunately for you, that's the case now. It's now time to wish you a well-deserved retirement. And thank you for all these years as a colleague and friend.

Lisa
37:59 - 38:49

Indeed, I want to thank Jerry warmly for these years, not only as a CFO but for working with me in events like this. And every day we work very, very closely. But I have had the privilege to work with Jerry for more than 20 years, you know, as a colleague. And now we work very closely together. And I couldn't find a CFO I hope I find a good CFO, but to date, I can only say that it's really been brilliant. And I have had full trust. And it's been a privilege to start a CEO career with such an experienced CFO who has the patience to explain things and take you through the initial steps. So I wish you all the best for your coming career. Thank you so much.

Jerry
38:49 - 39:20

Thank you, Lisa, for your nice words. And I also want to thank many of the people in the audience who I have had the privilege to work with for so many years. It's great to have good analysts who know the company and ask tough questions for us to answer because that also helps us to develop our thinking. But these have been very nice years, and like Luca said, all good things come to an end at some point, and now it's time to move forward.

Unknown 1
39:22 - 39:31

Thank you. And thank you to the audience. Next time we will meet here on August 8th with the half-year report. So have a good summer everyone.

Lisa
39:32 - 39:32

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…